The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.

SIFI, an Italian ophthalmology company focused mostly on the European market, doesn’t normally make it out to San Francisco ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Purdue Pharma and the Sackler family who own the company have proposed a new $7.4 billion settlement to resolve thousands of ...

The new business venture of Spotify founder Daniel Ek – Neko Health – has raised $260 million to bring its full body-scanning ...

2025 is going to be a year of great change. At a macro level, political and geopolitical shifts around the world will reshape ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as ...

US health insurance giant UnitedHealth Group has appointed company veteran Tim Noel as chief executive of UnitedHealthcare, ...

The story of HCPs’ advocacy for the Treat and Reduce Obesity Act reveals a broader truth: HCPs care deeply about the ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

One reason is the fact that much research related to ovarian cancer has focused on strategies combining chemotherapy with ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...